These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16944256)

  • 1. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
    Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.
    Takechi K; Yanagawa H; Zamami Y; Ishizawa K; Tanaka A; Araki H
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT; Liao HI; Wu Lin FL; Chang SC
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose regimen to achieve novel target trough concentration in teicoplanin.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
    J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
    Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
    J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
    Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
    Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections.
    Bantar C; Durlach R; Nicola F; Freuler C; Bonvehí P; Vazquez R; Smayevsky J
    J Antimicrob Chemother; 1999 May; 43(5):737-40. PubMed ID: 10382901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified chart for determining the initial loading dose of teicoplanin in critically ill patients.
    Yoshida S; Suzuki A; Ohmori T; Niwa T; Okada H; Suzuki K; Kobayashi R; Doi T; Kitaichi K; Matsuura K; Murakami N; Ogura S; Itoh Y
    Pharmazie; 2017 Jan; 72(1):53-57. PubMed ID: 29441898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.
    Rouveix B; Jehl F; Drugeon H; Brumpt I; Caulin E
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2394-9. PubMed ID: 15215086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.
    Pea F; Viale P; Candoni A; Pavan F; Pagani L; Damiani D; Casini M; Furlanut M
    Clin Pharmacokinet; 2004; 43(6):405-15. PubMed ID: 15086277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus.
    Hagihara M; Umemura T; Kimura M; Mori T; Hasegawa T; Mikamo H
    J Infect Chemother; 2012 Feb; 18(1):10-6. PubMed ID: 21710160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated methicillin-resistant staphylococcus aureus infection.
    Zhang XS; Chen YL; Wang YZ; Chen C; Chen YJ; Xu FM; Dai Y; Shi DW; Lin GY; Yu XB; Xiang DZ; Zhang CH
    Br J Clin Pharmacol; 2024 Feb; 90(2):452-462. PubMed ID: 37749762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
    Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
    BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis.
    Brink AJ; Richards GA; Cummins RR; Lambson J;
    Int J Antimicrob Agents; 2008 Nov; 32(5):455-8. PubMed ID: 18718742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.